CL2021002427A1 - Vector y método de tratamiento del síndrome de angelman - Google Patents

Vector y método de tratamiento del síndrome de angelman

Info

Publication number
CL2021002427A1
CL2021002427A1 CL2021002427A CL2021002427A CL2021002427A1 CL 2021002427 A1 CL2021002427 A1 CL 2021002427A1 CL 2021002427 A CL2021002427 A CL 2021002427A CL 2021002427 A CL2021002427 A CL 2021002427A CL 2021002427 A1 CL2021002427 A1 CL 2021002427A1
Authority
CL
Chile
Prior art keywords
vector
angelman syndrome
treatment
treat
ube3a
Prior art date
Application number
CL2021002427A
Other languages
English (en)
Inventor
Antonio Arulanandam
Kevin Nash
Edwin Weeber
Liangxian Cao
Min Jung Kim
Original Assignee
Ptc Therapeutics Inc
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc, Univ South Florida filed Critical Ptc Therapeutics Inc
Publication of CL2021002427A1 publication Critical patent/CL2021002427A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un aspecto descrito en el presente documento se refiere a un vector de virus adenoasociado recombinante (rAAV) y un método para su uso para tratar el síndrome de Angelman. Otro aspecto descrito en el presente documento es un vector de rAAV de UBE3A y un método para su uso para tratar una deficiencia de UBE3A, p. Síndrome de Angelman, en humanos.
CL2021002427A 2019-03-21 2021-09-16 Vector y método de tratamiento del síndrome de angelman CL2021002427A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962821442P 2019-03-21 2019-03-21

Publications (1)

Publication Number Publication Date
CL2021002427A1 true CL2021002427A1 (es) 2022-07-01

Family

ID=72521277

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002427A CL2021002427A1 (es) 2019-03-21 2021-09-16 Vector y método de tratamiento del síndrome de angelman

Country Status (17)

Country Link
US (1) US20220152223A1 (es)
EP (1) EP3941530A4 (es)
JP (1) JP2022525564A (es)
KR (1) KR20210145180A (es)
CN (1) CN114206393A (es)
AR (1) AR118481A1 (es)
AU (1) AU2020240136A1 (es)
BR (1) BR112021018354A2 (es)
CA (1) CA3133455A1 (es)
CL (1) CL2021002427A1 (es)
CO (1) CO2021013967A2 (es)
EA (1) EA202192543A1 (es)
IL (1) IL286476A (es)
MX (1) MX2021011198A (es)
SG (1) SG11202109736RA (es)
TW (1) TW202102672A (es)
WO (1) WO2020191366A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210158859A (ko) * 2019-05-22 2021-12-31 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Ube3a 유전자 및 발현 카세트 및 이들의 용도
WO2022272171A2 (en) * 2021-06-25 2022-12-29 University Of South Florida Secreted ube3a for treatment of neurological disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092582A1 (en) * 2000-06-01 2001-12-06 Genaissance Pharmaceuticals, Inc. Haplotypes of the ube3a gene
WO2010017515A2 (en) * 2008-08-08 2010-02-11 Integrated Diagnostics Inc. Breast cancer specific markers and methods of use
US9546369B2 (en) * 2010-04-23 2017-01-17 University Of Massachusetts Multicistronic expression constructs
JP5704361B2 (ja) * 2010-10-27 2015-04-22 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
WO2015060722A1 (en) * 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
SI3119437T1 (sl) * 2014-03-21 2020-01-31 Genzyme Corporation Genska terapija za retinitis pigmentoza
WO2016071911A1 (en) * 2014-11-06 2016-05-12 Yeda Research And Development Co. Ltd. Treatment of cns inflammatory disorders
WO2016179584A1 (en) * 2015-05-07 2016-11-10 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome
HRP20231451T1 (hr) * 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
US20200138921A1 (en) * 2017-06-23 2020-05-07 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease
CN110869031A (zh) * 2017-06-28 2020-03-06 南佛罗里达大学 用于天使人综合征的基因治疗方法的修饰的ube3a基因

Also Published As

Publication number Publication date
EA202192543A1 (ru) 2021-12-27
CA3133455A1 (en) 2020-09-24
IL286476A (en) 2021-12-01
WO2020191366A1 (en) 2020-09-24
KR20210145180A (ko) 2021-12-01
EP3941530A1 (en) 2022-01-26
CO2021013967A2 (es) 2022-02-28
US20220152223A1 (en) 2022-05-19
AR118481A1 (es) 2021-10-06
CN114206393A (zh) 2022-03-18
EP3941530A4 (en) 2022-12-14
TW202102672A (zh) 2021-01-16
JP2022525564A (ja) 2022-05-17
MX2021011198A (es) 2022-03-04
AU2020240136A1 (en) 2021-09-30
SG11202109736RA (en) 2021-10-28
BR112021018354A2 (pt) 2021-11-23

Similar Documents

Publication Publication Date Title
CL2021002427A1 (es) Vector y método de tratamiento del síndrome de angelman
CL2022003763A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
CY1123211T1 (el) Meθοδoi γia th θepaπeytikh antimetωπισh ή thn προληψη thς hmikpaniaς
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
EA201791775A1 (ru) Цистеиновая протеаза
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
BR112022007677A2 (pt) L-asparaginase recombinante
BR112016008331A2 (pt) composição para tratar e prevenir hiperplasia prostática benigna
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
AR116569A1 (es) Terapia génica para tratar la acidemia propiónica
CY1124507T1 (el) Νεος αναστολεας μεκ για τη θεραπευτικη αγωγη των ιικων και βακτηριακων λοιμωξεων
BR112022001912A2 (pt) Composições celulares compreendendo vetores virais e métodos de tratamento
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
EA201890163A1 (ru) Композиция фолликулостимулирующего гормона млекопитающего с повышенной стабильностью
AR119271A1 (es) Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada
BR112019003816A2 (pt) composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição
EA202092045A1 (ru) Лечение и предупреждение преэклампсии
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
BR112022011276A2 (pt) Biomolécula para tratamento de patologias da córnea
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia
TR201722950A2 (tr) Koah tedavisinde yeni farmasötik bileşimler.